DOI: http://dx.doi.org/10.18203/2349-3933.ijam20202123

Effect of ART2 on the CD4 count and viral load during treatment of second line ART

Narendra Singh, R. K. Varma, Richa Giri, Punit Varma, Seema Dwivedi, Lalit Kumar

Abstract


Background: AIDS first recognized in US summer of 1981 by the U.S. CDC reported. In 1983 HIV was isolated from a patient of lymphadenopathy. This study was for monitoring the change in CD4 count and viral load of PL HIV before and after one year of second line ART in the period of 2016 to 2018.

Methods: Study was single centre hospital based and clinical continuous longitudinal, prospective and retrospective, observational at ART plus Centre, Kanpur K.P.S. Institute of Medicine (G.S.V.M. medical college Kanpur) included the all patients on ART1 attending in centre were screened for treatment failure based on clinical, immunological and virological criteria’s as decided by SACEP from 2016 to 2018.

Results: CD4 count at the time of initiation that of second line ART, there is low CD4 count the mean value is 181.44±85.02 in total subject 118 but 12 month of second line ART 2 treatment mean value of CD4 count 413.01±168.70. After Z test  application  the  value is 13.316, p value 0.0001, MD 231.5, CI is 95%.Viral load value at time of start of second line  ART  mean value is 80683.85849±293449.2038, after 1 to 12 month of start  of  second line ART treatment mean value is 350.8559±128.1069, for this Z value is 2.972, p value 0.0033.

Conclusions: Second line ART is most effective in treatment after failure with first line ART. CD 4 count increase and viral load decrease and clinical feature improve after treatment of ART 2.


Keywords


Acquired immune deficiency syndrome, Antiretroviral therapy, CDC, Human immunodeficiency virus, South Asian Cooperative Environment Programme

Full Text:

PDF

References


Palacios R, Vergara S, Rivero A, Aguilar I, Macías J, Camacho A, et al. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV clinical trials. 2006 Dec 1;7(6):319-23.

Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007 Apr 7;369(9568):1169-78.

Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine. Longo DL, editor. New York: Mcgraw-hill; 2012.

Walker BR, Colledge NR. Davidson's Principles and Practice of Medicine E-Book. Elsevier Health Sciences; 2013.

Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS. 2007 Jan 30;21(3):325-33.

Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS. HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. JAIDS. 2007 May 1;45(1):4-8.

Sungkanuparph S, Manosuth W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a Second-Line Antiretroviral Regimen for HIV Type 1-Infected Patients Whose Initial Regimen of a Fixed-Dose Combination of Stavudine, Lamivudine, and Nevirapine Fails. Clini Infect Dis. 2007;44(3):447-52.

Patel D, Desai M, Shah AN, Dikshit RK. Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients. Perspectives Clini Res. 2013 Oct;4(4):215-20.